Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 16.33 is 13% above its 2-year average of 14.50, near the high end of its 2-year range (7.37–19.49).
As of the fiscal period ended Tuesday, June 30, 2026. 24.50% above its 12-month average of 13.11.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 16.33.
QUICK RATIO (ACID-TEST)
16.33
QUICK RATIO (ACID-TEST) AVG TTM
13.11
QUICK RATIO (ACID-TEST) AVG 3Y
N/A
QUICK RATIO (ACID-TEST) AVG 5Y
N/A
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+24.50%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
2.83
median of 454 covered companies
CURRENT VS SECTOR MEDIAN
+477.93%
vs the sector median at left
Aktis Oncology, Inc.
Market Cap
$989.05M
Quick Ratio (Acid-Test)
16.33
TTM Avg
13.11
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$985.79M
Quick Ratio (Acid-Test)
8.42
TTM Avg
11.89
3Y Avg
15.48
5Y Avg
17.00
Market Cap
$1.03B
Quick Ratio (Acid-Test)
1.98
TTM Avg
1.08
3Y Avg
1.74
5Y Avg
1.96
Market Cap
$943.26M
Quick Ratio (Acid-Test)
8.79
TTM Avg
12.77
3Y Avg
8.84
5Y Avg
8.84
Market Cap
$1.05B
Quick Ratio (Acid-Test)
0.81
TTM Avg
2.16
3Y Avg
2.71
5Y Avg
2.89
Market Cap
$922.50M
Quick Ratio (Acid-Test)
81.42
TTM Avg
11.94
3Y Avg
8.59
5Y Avg
10.34
Market Cap
$921.45M
Quick Ratio (Acid-Test)
1.06
TTM Avg
1.14
3Y Avg
1.09
5Y Avg
1.06
Market Cap
$915.95M
Quick Ratio (Acid-Test)
1.17
TTM Avg
1.03
3Y Avg
0.92
5Y Avg
1.05
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aktis Oncology, Inc. (AKTS) | $989.05M | 16.33 | 13.11 | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | 8.42 | 11.89 | 15.48 | 17.00 |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | 1.98 | 1.08 | 1.74 | 1.96 |
| CeriBell, Inc. (CBLL)vs › | $943.26M | 8.79 | 12.77 | 8.84 | 8.84 |
| Immatics N.V. (IMTX)vs › | $1.04B | 7.54 | 10.49 | 6.85 | 5.34 |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | 0.81 | 2.16 | 2.71 | 2.89 |
| Arbutus Biopharma Corp (ABUS)vs › | $922.50M | 81.42 | 11.94 | 8.59 | 10.34 |
| HealthStream, Inc. (HSTM)vs › | $921.45M | 1.06 | 1.14 | 1.09 | 1.06 |
| Bioventus Inc. (BVS)vs › | $915.95M | 1.17 | 1.03 | 0.92 | 1.05 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | 16.16 | 3.88 | 3.97 | 4.50 |
Quick Ratio
16.33
Excludes inventory
Current Ratio
16.33
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 16.33 |
| 2026-03-31 | 19.49 |
| 2025-12-31 | 7.37 |
| 2025-09-30 | 9.27 |
| 2024-12-31 | 15.98 |
| 2024-09-30 | 18.55 |
